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Abstract
Vaccines against many pathogens for which conventional approaches have failed remain an unmet public health priority.
Synthetic peptide-based vaccines offer an attractive alternative to whole protein and whole organism vaccines, particularly
for complex pathogens that cause chronic infection. Previously, we have reported a promising lipid core peptide (LCP)
vaccine delivery system that incorporates the antigen, carrier, and adjuvant in a single molecular entity. LCP vaccines have
been used to deliver several peptide subunit-based vaccine candidates and induced high titre functional antibodies and
protected against Group A streptococcus in mice. Herein, we have evaluated whether LCP constructs incorporating defined
CD4+ and/or CD8+ T cell epitopes could induce epitope-specific T cell responses and protect against pathogen challenge in
a rodent malaria model. We show that LCP vaccines failed to induce an expansion of antigen-specific CD8+ T cells following
primary immunization or by boosting. We further demonstrated that the LCP vaccines induced a non-specific type 2
polarized cytokine response, rather than an epitope-specific canonical CD8+ T cell type 1 response. Cytotoxic responses of
unknown specificity were also induced. These non-specific responses were able to protect against parasite challenge. These
data demonstrate that vaccination with lipid core peptides fails to induce canonical epitope-specific T cell responses, at
least in our rodent model, but can nonetheless confer non-specific protective immunity against Plasmodium parasite
challenge.
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Introduction
Vaccines are one of the most cost effective and efficient health
care interventions for the prevention of infectious diseases. Almost
all licensed vaccines are based on the delivery of live, attenuated,
or killed whole pathogens. Vaccines which contain the minimal
microbial components necessary to stimulate appropriate immune
responses are referred to as subunit vaccines. Subunit vaccines
have a range of advantages over the use of whole pathogenic
microorganisms, including: improved stability, reduced risk of
autoimmunity and allergic responses, no risk of reversion to the
virulent form, ability to direct immune responses towards a
specified antigen or epitope, and capacity for large-scale produc-
tion under good manufacturing conditions [1,2]. Recombinant
protein-based subunit vaccines have been widely evaluated in
many disease systems, including malaria [3]. However, the leading
asexual blood-stage and liver-stage recombinant protein subunit
vaccines candidates against malaria (MSP1, AMA1 and LSA1)
have all failed in recent phase 2a experimental challenge studies
and phase 2b field trials [4] despite induction of high antibody
titre, growth inhibitory activity, and CD4+ T cell responses. Such
failures highlight the need for a redirection of subunit vaccine
approaches.
Synthetic peptide-based vaccines offer many advantages over
whole-organism vaccines due their amenability to large-scale
production, their well-defined composition and purity, and their
suitability for freeze-drying which eliminates the need for the cold-
chain. Further advantages of epitope-based vaccines over current
vaccines include increased potency and other qualitative aspects of
the immune response, particularly when compared to the use of
whole antigens. Epitope-based immunization has been shown to
be effective in eliciting responses against multiple B cell, CD4+ T
cell or CD8+ T cell epitopes, including subdominant CD8+ T cell
epitopes [5–13]. Most importantly, the epitope approach has been
used successfully to treat and/or prevent different types of disease
in animal models, including acute or chronic viral infections
[6,7,14,15], parasitic and microbial infections [16], and cancer
[17].
However, peptides have limited immunogenicity because the
exclusion of other pathogen components often removes the
‘‘danger signal’’ [18] necessary to trigger an immune reaction.
To overcome this problem an adjuvant is usually required for
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peptide-based subunit vaccine efficacy. Adjuvants based on
aluminium salts remain the principal compounds licensed for
human use [19]. However, aluminium adjuvants are quite weak
immune stimulants, unstable when freeze-dried, and possess some
toxicity. In contrast, highly efficient adjuvants used experimentally
in animal models or for veterinary use are often toxic and are
therefore unsuitable for human use. Moreover, there are currently
no adjuvants licensed for human use that were designed to
specifically enhance cell mediated immune responses; critical for
the control of many pathogens, including intracellular parasites
such as Plasmodium [20]. These concerns have prompted us to
develop self-adjuvanting lipopeptide vaccine delivery systems
[21,22,23]. The Lipid Core Peptide (LCP) incorporates a
lipoamino acid-based non-microbial lipidic adjuvant with a poly-
lysine multiple antigenic peptide (MAP) system [24] which allow
the conjugation of multiple copies of peptide antigens. In contrast
to palmitoyl-conjugated lipopeptides [25,26,27,28], the LCP
delivery system incorporates three major persistent components:
a) a non-microbial lipopeptide moiety (composed of synthetic
lipidic amino acids (LAAs)), which may be arranged into the
peptide sequence with a glycine spacer; b) a branching moiety
(usually based on polylysine); and c) appropriate peptide epitopes
[29]. The lipidic self-adjuvanting moiety can be easily modified in
terms of the presence of a spacer, the number of LAAs, and the
length of their alkyl chains. The lysine branching allows the
advantageous use of a MAP system. The level of the branching can
be adjusted to suit the requirements. The lysine carrier permits the
conjugation of multiple copies of the same peptide epitope as well
as conjugation of many different peptide antigens [30]. It has been
shown that the number of LAA and the length of alkyne chain of
each LAA can control induction of antibody production. To this
end, an optimal LCP structure for vaccine delivery has been
defined [23]. Studies have reported that the LCP core (lipidic part
of LCP) does not induce immune responses, with or without
‘‘irrelevant’’ peptide [23,31] and that a physical mixture (in
contrast to conjugation) of peptide epitope and lipidic part of the
LCP does not stimulate any immune responses [31].
The LCP-based constructs can be stored in a freeze-dried form
at room temperature and are stable to a wide range of peptidases.
Lipid core peptide synthesis can be achieved using classical solid-
phase peptide synthesis with only a single purification after the
cleavage of the resultant peptide from the solid support. The
physicochemical and immunological properties of LCP systems
can be readily altered by changing a nature and number of
lipoamino acids, degree of poly-lysine branching, and by
attachment of targeting moieties such as carbohydrates [32,33].
This system can also incorporate two or more different epitopes
attached to the one carrier molecule [31].
LCP vaccines have proved effective inducers of antibody
responses in animal models of Chlamydia and Group A strepto-
coccus [31,34–36] but, despite the importance of T cells for
control of many infectious diseases, their capacity to induce robust
CD4+ or CD8+ T cell responses has not yet been established [20].
Furthermore, CD4+ T cell help may be required for optimal CD8+
T cell activity [37,38] although this requirement is not absolute
[39–41]. Thus, vaccines are usually designed to include either
pathogen-specific CD4+ T cell helper epitopes (as in the case of
full-length or partial length recombinant protein subunit vaccines)
or ‘‘universal’’ (promiscuous) CD4+ T helper epitopes such as
PADRE [42,43]. For diseases where vaccine-induced immune
responses may be boosted by natural exposure, such as malaria,
inclusion of pathogen-specific CD4+ T cell epitopes is desired. For
Plasmodium, CD4+ and CD8+ T cell epitopes typically map to
similar or overlapping regions [44,45].
The Plasmodium yoelii rodent model of malaria is an ideal system
in which to evaluate the potential of LCP T cell epitope-based
vaccine constructs. Malaria, caused by infection with parasites of
the genus Plasmodium, remains a significant public health problem
with approximately half of the world’s population at risk of the
disease [46,47]. The development of a malaria vaccine remains a
high global health priority. The feasibility of developing a malaria
vaccine is supported by data showing that sterile infection-blocking
immunity can be achieved by experimental immunization with
radiation-attenuated Plasmodium spp. sporozoites in mice and
humans (reviewed in [48]) or by immunization with infectious
sporozoites under the cover of drug prophylaxis [49–51]. Studies
in animal models have implicated CD8+ T cells as critical effector
cells in this protection (based on in vivo depletion, reconstitution,
and adoptive transfer studies), and CD4+ T cells have also been
implicated with an important role in both the induction and
effector phases (reviewed in [52]). IFN-c has been identified as a
critical mediator of the irradiated sporozoite induced protection
[53,54].
A CD8+ T cell epitope on the sporozoite coat protein of P. yoelii,
the circumsporozoite protein (PyCSP amino acids 280–288,
sequence SYVPSAEQI), has been identified as the target of
CD8+ cytotoxic T lymphocytes (CTL) that can eliminate infected
hepatocytes from in vitro culture in an antigen-specific and
genetically-restricted manner [55,56]. Furthermore, in vivo adop-
tive transfer of CD8+ CTL against this epitope can protect against
sporozoite-induced malaria in the absence of other parasite-
specific immune responses [57,58]. This epitope is the immuno-
dominant epitope recognized by BALB/c (H-2d) mice immunized
with radiation attenuated paasites, recombinant viral constructs,
or plasmid DNA encoding PyCSP [55,57–64] and in vitro CTL
activity and IFN-c production specific for this epitope correlate
with protective immunity [61]. This CD8+ T cell epitope is nested
within a dominant CD4+ T cell epitope (amino acids 280–295,
sequence SYVPSAEQILEFVKQI). Another dominant CD4+ T
cell epitope(s) has also been identified on PyCSP (amino acids 57–
70, sequence KIYNRNIVNRLLGD) and immunization of mice
with a multiple antigenic peptide based on this epitope induced
proliferative T cell responses, CTL capable of eliminating infected
hepatocytes in vitro, and conferred partial protection against
sporozoite challenge [65]. The CTL response was specific for a
subdominant CD8+ T cell epitope mapped to residues 58–67
(sequence IYNRNIVNRL) that is recognized following immuni-
zation with the multiple antigen peptide [65] but not in the context
of whole CSP immunization after immunization with either the
whole organism (irradiated sporozoite) or whole antigen (plasmid
DNA). Immunization with a synthetic peptide corresponding to
the partially overlapping Py1 epitope (amino acids 59–79,
sequence (YNRNIVNRLLGDALNGKPEEK)) [66] primed
CD4+ T cells as well as CD8+ T cells which could eliminate
parasites from infected hepatocytes in vitro [63]. This CD8+ T cell
response is likely directed against the 9 mer subdominant CD8+ T
cell epitope (residues 59–67, sequence YNRNIVNRL) [65].
Accordingly, we have evaluated the immunogenicity and protec-
tive capacity of LCP-based constructs expressing different
combinations of these four well defined CD8+ and/or CD4+ T
cell epitopes from PyCSP (Table 1).
Materials and Methods
Synthetic peptides and plasmid DNA
Synthetic peptides representing each of the defined CD4+ and/
or CD8+ T cell epitopes from PyCSP were synthesized commer-
cially (Mimotopes) at .80% purity. Plasmid DNA encoding full-
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length PyCSP, based on the VR1020 backbone, has been
described previously [67].
Design and Synthesis of the Lipid core peptide (LCP)
Vaccines
Lipid core peptide (LCP) vaccines were prepared by solid-phase
peptide synthesis according to previously reported procedures
[36,68] at 20–40 mg each. Four LCPs were constructed (Figure 1).
LCP1 contained two copies each of the 9 mer CD8+ T cell
dominant epitope nested within a dominant CD4+ T cell epitope
(280–288) and the 10 mer subdominant CD8+ T cell epitope (58–
67). LCP2 contained two copies each of the 9 mer CD8+ T cell
dominant epitope (280–288) and the 10 mer subdominant CD8+
T cell epitope (58–67). LCP3 contained two copies each of the
9 mer CD8+ T cell dominant epitope (280–288) and the 10 mer
subdominant CD8+ T cell epitope nested within a dominant CD4+
T cell epitope (55–70). LCP4 contained two copies each of the two
dominant CD4+ T cell epitopes (57–70 and 280–295).
Haemolytic assay
Since LCP compounds incorporate hydrophobic lipid moieties
and hydrophilic peptide epitopes, they have amphiphilic (surfac-
tant-like) properties. Therefore the capacity of the LCP com-
pounds to induce haemolysis was examined in a standard
haemolytic assay. In brief, blood collected from a healthy human
volunteer with written informed consent (protocol approved by the
University of Queensland Ethics Committee, approval number
2009000661) was centrifuged at 750 g for 15 min and washed with
PBS (Gibco-BRL) until the suspension was transparent. The red
blood cell pellet was resuspended to original volume with PBS and
100 mL of red blood cell solution added per well in a 96-well plate
(Greiner CELLSTARH). Subsequently, 100 mL of each LCP
construct at 10 mM, 50 mM, and 200 mM concentration was
added to triplet wells and incubated at 37uC for 1 h. SDS and PBS
control treatments were assayed in parallel. After 1 h, the plate
was centrifuged at 750 g for 15 min and then 75 mL of supernatant
per well was transferred to a new 96-well plate and measured by
UV spectrometer at 540 nm wavelength. The percentage of
hemolysis was evaluated by comparing the absorbance (540 nm) of
the vaccine candidates with that of negative control (SDS, 100%
hemolysis) and positive control (PBS, 0%). Data were analysed
according to the following formula:
% Haemolysis~(A540{min540=max540{min 540)|100
It was clearly demonstrated that the LCP constructs are not
haemolytic even at high concentration (200 mM) (Figure S1).
Animals and Parasites
Specific pathogen-free female BALB/c mice (Animal Resources
Centre, Perth, Australia) were used at 6–9 weeks of age. Female
CS-TCR transgenic mice (BALB/c background) were kindly
provided by Prof. Fidel Zavala (Johns Hopkins University,
Baltimore, USA); the CS-TCR mouse has been engineered so
that the TCR is specific for the immunodominant CD8+ T cell
epitope from Plasmodium yoelii CSP (residues 280–288) [69].
C57BL/6 RAG-22/2cc2/2 were bred at QIMR. All studies
were approved by the QIMR Animal Ethics Committee and were
conducted in accordance with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes (2004).
Immunizations and adoptive transfer studies
Mice were immunized subcutaneously (s.c.) one to three times
with 30 mg LCP at 3 week intervals and assessed for immunoge-
nicity or protective efficacy against Plasmodium yoelii sporozoite
Table 1. CD4+ and CD8+ T cell epitopes from P. yoelii circumsporozoite protein (PyCSP).
Peptide Origin mer Amino acid sequence Kd IC50 (nM) [91] Epitope characteristics Ref
P1 PyCSP280–288 9 SYVPSAEQI 2.2 Immunodominant CD8 [55,56]
P2 PyCSP280–295 16 SYVPSAEQILEFVKQI 463 CD4 dominant/CD8 dominant [55]
P3 PyCSP58–67 10 IYNRNIVNRL 16 subdominant CD8 [65]
P4 PyCSP57–70 14 KIYNRNIVNRLLGD 8,250 CD4 dominant/CD8 subdominant [65,92]
doi:10.1371/journal.pone.0040928.t001
Figure 1. Schematic representation of lipid core peptide (LCP) constructs. Epitopes from P. yoelii circumsporozoite protein (PyCSP) as
follows: P1 = PyCSP280–288, SYVPSAEQI; P2 = PyCSP280–295, SYVPSAEQILEFVKQI; P3 = PyCSP58–67, IYNRNIVNRL; P4 = PyCSP57–70, KIYNRNIVNRLLGD. See
Materials and Methods and Table 1 for additional details.
doi:10.1371/journal.pone.0040928.g001
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challenge at 11–14 days post final immunization. For the former,
mice were sacrificed and splenocytes and lymph nodes were
harvested, processed and assayed for phenotypic markers or
cytokine response. In some studies, CD8+ T cells (50,000) purified
from naı¨ve-CS-TCR transgenic mice were adoptively transferred
via intravenous (i.v.) injection into the tail vein of naı¨ve BALB/c
mice 2 days prior to LCP immunization. At 7 days post
vaccination, splenocytes and draining lymph nodes were harvested
and the presence and function of donor CD8+ T cells were
analysed by flow cytometry. Alternatively, mice were immunized
s.c. with matched doses of synthetic peptides in CpG/alum (CpG
ODN 1826, 50 mg/dose (Sigma Aldrich) mixed 1:1 with
AlhydrogelH (Brenntag Biosector, Frederikssund, Denmark) given
in a 200 ml dose) or intramuscularly (i.m.) in each tibialis anterior
muscle with 50 mg of PyCSP plasmid DNA.
Flow cytometry and analysis
Cells were incubated on ice with combinations of fluorochrome-
conjugated Ab to CD8+ells were incubated on ice with
combinations of fluorochrome-conjugated Ab to CD8e presence
and function of donor CD8ice dies, ice for the Care and Use of
Animals with 1 mg/ml propidium iodide (Calbiochem, San
Diego, CA). CD8+ T cells were purified using a MoFlo cytometer
(DakoCytomation, Glostrup, Denmark) with exclusion of dead
cells based on forward scatter and propidium iodide uptake. Flow
cytometric analysis was performed on a FACSCalibur (BD
Biosciences, North Ryde, NSW, Australia) or FACSCanto II
(BD Biosciences) with standard optics configuration (405 nm violet
laser, 488 nm blue laser, 633 nm red laser) with CellQuest version
3.1F software (BD Biosciences, San Jose, CA). Post-acquisition
data analysis was performed with FlowJo software version 9.1
(Treestar, Ashland, OR, USA) or Summit Software V4.3
(DakoCytomation). Calculations were performed using Microsoft
Excel (version 12, Microsoft Corporation, WA, USA) or Prism
GraphPad software V5.0 (La Jolla, CA, USA).
Cytometric bead array
Splenocytes from vaccinated mice were cultured with each of
the synthetic peptides representing the defined CD8+ or CD4+ T
cell epitopes, ConA, or media only, for three days. Culture
supernatants from individual mice were collected and cytokines
were analysed according to the manufacturer’s instructions using
the cytometric bead array (CBA) (BD Biosciences). Analysis was
performed on a FACSarray cytometer equipped with CellQuest
Pro and CBA software (BD Biosciences).
CTL assay
To assess cytotoxic capacity, splenocytes harvested seven days
post-vaccination were restimulated for three days with synthetic
peptides representing the dominant CD8+ T cell epitope (P1;
CSP280–288). To assess cytolytic function the splenocytes were
incubated for 4–5 hours at the ratio of 100:1 with CFSE stained
target cells of the A20 cell line that had been pre-incubated for
60 minutes with the P1 peptide or anti-receptor monoclonal
antibody 2C11. Cytolytic function was determined by flow
cytometric assessment of the percentage of CFSE labeled target
cells that were propidium iodide positive at the completion of the
incubation, as described previously [70].
Flow-based antibody assay
Serum antibody levels were determined by flow cytometric
evaluation of median fluorescence intensity (MFI) of parasite
extract incubated with serum and then stained with fluorescently
labelled secondary antibodies to pan-Ig or specific isotypes detailed
below.
For preparation of extract, P. yoelii YM was grown in RAG-22/
2 cc2/2 mice (deficient in T, B, and NK cells) to approximately
75% parasitemia. Blood was collected from anesthetized mice by
cardiac puncture into 10 volumes of FCAB buffer [71] prepared
from PBS with 2 mM EDTA and 0.5% heat inactivated FBS stock
solutions (Sigma–Aldrich, Castle Hill, NSW, Australia). Samples
were centrifuged at 600 RCF for 10 minutes, aspirated and
resuspended in 0.5% w/v saponin, and incubated for 30 minutes
at 37uC. The sample was drawn twice through a 30 gauge needle
before being washed twice with 20 volumes of Milli-Q H20 and
centrifuged as above. The sample was then fixed in FCAB fixation
and lysis buffer [71] for 10 minutes at 37uC. FCAB fixation and
lysis buffer prepared from PBS with 4% w/v paraformaldehyde
and 0.0067% w/v saponin (both Sigma-Aldrich). The extract was
resuspended in FCAB buffer and stored at 220uC until required.
All buffers were sterile filtered (0.2 mm) before use.
For the assay, 3 ml blood samples were collected and diluted in
1 ml of FCAB buffer as described [71]. Serum supernatant from
centrifuged blood samples was incubated with extract for
10 minutes at 4uC in 96-well v-bottom plates, washed with three
volumes of FCAB buffer and then stained with a cocktail of anti-Ig
antibodies for ten minutes at 4uC: anti-IgG2a-FITC (clone R19-
15), anti-IgM-PE/Cy7 (clone R6-60.2), anti-IgG1-APC (clone
A85-1), and GAM-FITC (poly 554001) (all BD Biosciences); and
anti-IgE-PE (clone RME-1) and GAM-APC/Cy7 (poly 4053)
(both Biolegend). Following another wash, the samples were
resuspended in 35 ml of FCAB buffer and analysed on FACS-
Canto II (BD Biosciences, North Ryde, NSW, Australia) equipped
with HTS plate reader. Post-acquisition data analysis was
performed with FlowJo software version 9.1 (Treestar, Ashland,
OR, USA); calculations were performed using Microsoft Excel
(version 12, Microsoft Corporation, WA, USA). Relative Ab
fluorescence intensity was determined by dividing the MFI of the
sample serum by the mean MFI of serum samples from five naı¨ve
mice at each time point.
In vivo protection
Mice were challenged by tail-vein injection with 1000 cryopre-
served infectious P. yoelii sporozoites (17XNL non-lethal strain)
(Sanaria Inc., Rockville, MD, USA). For evaluation of partial
protection at the liver-stage, mice were euthanized at 42 hours
after challenge and the liver-stage parasite burden assessed using
an assay modified from that described previously [72]. Briefly, the
livers were collected and homogenized in RLT Buffer (Qiagen)
and aliquots of liver RNA extracted using RNAeasyH Mini Kits
(Qiagen). cDNA was synthesised using SuperScript VILO cDNA
Synthesis Kit (Invitrogen). Parasite RNA was extracted and P. yoelii
18S ribosomal RNA quantified by quantitative real time PCR
(Py18S 59 primer Py685F 59-CTTGGCTCCGCCTCGATAT;
Py18S 39 primer Py782R 59-TCAAAGTAACGAGAGCC-
CAATG; Py18S probe 6FAM-CTGGCCCTTTGAGAGCC-
CACTGATT-BHQ-1); b2-microglobulin was quantified using
TaqManH. An estimate of P. yoelii 18S rRNA ‘‘plasmid equiva-
lents’’ and mouse b2-microglobulin (housekeeping gene) ‘‘plasmid
equivalents’’ were derived from the Ct (Threshold Cycle)
measured for each PCR target for each unknown sample.
Quantitative parasite burden data was expressed as the ratio of
P. yoelii 18S rRNA plasmid equivalents over the mouse b2-
microglobulin plasmid equivalents for each sample. Alternatively,
sporozoite-infected mice were allowed to progress to blood-stage
parasitemia or were challenged with 16105 P. yoelii blood-stage
parasites, and the course of infection was monitored by a recently
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PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e40928
described multiparameter flow cytometry assay (FCAB assay) up to
day 35 post-challenge [71].
Statistical analyses
Assessment of statistical significance was performed using one-
way ANOVA with Bonferroni’s post-hoc test (Prism 4.02 software
package; Graph-Pad, San Diego, CA). Significance was defined at
the 5% level. Values of p are indicated in the figures by the
following symbols: NS, not significant, p..0.05; * p= 0.01–0.05; **
p= 0.001–0.01; *** p,0.001.
Results
PyCSP epitope-based LCP vaccines fail to induce antigen-
specific CD8+ T cell expansion
Initially we determined whether our lipid peptide core (LCP)
vaccines could induce the expansion of PyCSP-specific CD8+ T
cells by adoptively transferring naı¨ve Vb8.1+ Thy1.1+ CD8+ T
cells purified from CSP280–288-specific TCR-transgenic (CS-TCR)
mice into WT BALB/c hosts. Two days later the mice were
vaccinated s.c. with individual LCP (LCP1, LCP2, LCP3, or
LCP4), or a pool of cognate peptides representing the target T cell
epitopes formulated in CPG/alum (peptides 1–4, see Table 1
above), or i.m. with DNA vaccine encoding the PyCSP. Seven days
post vaccination, draining lymph nodes (DLN) and spleens were
harvested and donor cell presence assessed by flow cytometry.
Preliminary experiments first determined the optimal number of
cells for adoptive transfer to be 50,000 (data not shown) and this
was used in all subsequent experiments involving adoptive transfer.
The percentage of the CD8+ T cell population consisting of donor
cells was not increased in the spleen or DLN after a single
immunization with any vaccine.
To determine whether the expansion in antigen-specific CD8+
T cells could be enhanced by boosting, we adoptively transferred
naı¨ve CS-TCR CD8+ T cells into naı¨ve BALB/c hosts and
vaccinated mice as described above. Mice were then boosted at
three and six weeks after the initial vaccination. Seven days
following the third vaccination, the frequency of donor cells within
the spleens of DNA vaccinated mice was significantly increased
when compared to the no-vaccine control and other vaccine
groups and constituted approximately two percent of the entire
CD8+ T cell population (Fig. 2B), representing a near 10-fold
enhancement over levels following the primary vaccination
(Fig. 2A); a 2-fold enhancement was noted in the DLN. With
peptide-CpG/alum, CD8+ T cells were maintained at similar
levels in both spleen and DLN. In contrast, there was at least a 10-
fold reduction in CD8+ T cells in the spleen and 3–5 fold reduction
in CD8+ T cells in the DLN following LCP vaccinations. Donor
Figure 2. Antigen-specific donor CD8+ T cell expansion
following vaccination. Frequency of CS-TCR CD8+ T cells (with
specificity for the dominant CD8+ T cell epitope from P. yoelii
circumsporozoite protein, PyCSP280–288) within the draining lymph
nodes (DLN) and spleen (SPL) seven days after adoptive transfer into
congenic hosts and vaccination with a single s.c. injection of lipid core
peptides (LCP), or pooled peptides (P1, P2, P3, P4; see Table 1) and CpG-
Alum, or i.m. injection with DNA vaccine encoding PyCSP (D7) (A); or
seven days after the final of three similar vaccinations given at 3 week
intervals (W7) (B). Results (mean and SEM) with mice tested individually
are shown (A, SPL and DLN n= 6 mice pooled data from two repeat
experiments; B, SPL n = 5 mice from a representative experiment)
except for B, DLN which were pooled from five mice (mean shown).
Statistical comparisons are made to a control group that received
adoptively transferred cells but no vaccination (No Vacc Ctrl) or as
indicated on the graph, using one-way ANOVA with Bonferroni’s post-
test.
doi:10.1371/journal.pone.0040928.g002
Figure 3. IL-2 and IFN-c expressing T cells following vaccination. Frequency of CD4+ and CD8+ T cells expressing IL-2 and IFN-c following
PMA/ionomycin restimulation and intracellular staining of cells taken from the draining lymph nodes (DLN) and spleen (SPL) seven days after
vaccination with a single s.c. injection of lipid core peptides (LCP), or pooled peptides (P1, P2, P3, P4; see Table 1) and CpG-Alum, or i.m. injection with
DNA vaccine encoding PyCSP. Results pooled from two repeat experiments are shown (n= 6 mice, mean and SEM). Statistical comparisons are made
to a control group that received no vaccination (No Vacc Ctrl) using one-way ANOVA with Bonferroni’s post-test.
doi:10.1371/journal.pone.0040928.g003
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cells were no longer detectable in the spleens or DLN of
unvaccinated control mice at this time point.
LCP vaccines induce a non-specific type 2 polarized
response rather than a canonical CD8+ T cell type 1
response
To determine the effects of LCP vaccination on the functional
phenotype of the responding T cells, mice were vaccinated with
LCP vaccines or controls including p-CPG/alum or DNA vaccine
in a single or prime-boost strategy as described above. Seven days
after primary vaccination, IFN-c and IL-2 expression was assessed
by ICS following a 4.5 h PMA/ionomycin restimulation of T cells
recovered from spleens and DLNs (Fig. 3). DNA vaccination
significantly increased the frequency of CD8+ T cells and CD4+ T
cells producing IFN-c the spleen but not DLN and the frequency
of IL-2 producing CD4+ cells in the spleen. None of the other
vaccines had a consistent effect on T cell cytokine expression.
In parallel experiments, splenocytes harvested seven days
following the final prime-boost vaccination were cultured with
individual PyCSP peptides, or controls including ConA or media
only, for three days. Cytokine levels in the supernatant were
determined by Cytokine Bead Array (CBA) for a panel of
cytokines (Fig. 4). We first assessed whether vaccination had
affected the cytokine levels by comparing levels to the restimula-
tion-equivalent no-vaccine control (shown as asterisks when
significant). We then assessed whether any changes in cytokine
responses were peptide-specific by comparing levels to those
observed in controls that had received the same vaccinations but
were cultured without peptide or ConA (media only) (shown as Yes
(Y) or No (N); Yes indicating p,0.05).
In contrast to DNA, and consistent with the ICS data, LCP
vaccination failed to induce epitope-specific production of IFN-c
(Fig. 4). Rather, based upon the CBA data, the LCP vaccines
induced a predominantly type-2 polarized cytokine response, but
these responses were almost exclusively not epitope-specific.
To further investigate the functional ability of LCP vaccine
responding CD8+ T cells, a CTL assay was performed with
splenocytes harvested seven days after the final vaccination from
prime-boost vaccinated mice. Splenocytes from prime-boost LCP-
vaccinated mice failed to kill peptide-coated target cells, but were
Figure 4. Cytokine production following prime-boost vaccinations. Mice were vaccinated s.c. three times at three week intervals with lipid
core peptides (LCP), or pooled peptides (P1, P2, P3, P4; see Table 1) and CpG-Alum, or i.m. injection with DNA vaccine encoding PyCSP. Seven days
following the final vaccination the splenocytes were harvested and restimulated for three days with peptides as indicated. Cytokine levels in the
supernatant were then determined by Cytokine Bead Array. Asterisks indicate a significant increase in cytokine production when compared to the
restimulation-equivalent no-vaccine control. Y (yes) or N (no) indicate statistically significant (p =,0.05) increase in cytokine production when
compared to those observed in controls that had received the same vaccinations but were cultured without peptide or ConA (media only).
Significance determined using one-way ANOVA with Bonferroni’s post-test (n = 5).
doi:10.1371/journal.pone.0040928.g004
Figure 5. Antigen-specific CTL function following prime-boost
vaccination with Lipid Core Peptides. Mice were vaccinated s.c.
three times at three week intervals with lipid core peptides (LCP), or
pooled peptides (P1, P2, P3, P4; see Table 1) and CpG-Alum, or i.m.
injection with DNA vaccine encoding PyCSP. Seven days after the final
vaccination the splenocytes were harvested and restimulated for three
days with the dominant CD8+ T cell epitope (Pep 1, PyCSP280–288) and
then assessed for cytolytic potential by flow cytometry using A20 target
cells coated with Pep 1 (+Peptide) or anti-receptor antibodies (+2C11)
(see Materials and Methods). Results from a representative experiment
are shown (triplicate samples, mean and SEM).
doi:10.1371/journal.pone.0040928.g005
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able to kill anti-receptor Ab coated target cells (Fig. 5). These data
suggest that the LCP vaccines induced CTL responses of unknown
specificity.
Taken together, data show that the LCP vaccines did not induce
a canonical CD8+ T cell type 1 response directed against the
epitopes included in the constructs, but rather a non-specific type 2
polarized response.
LCP vaccination modifies the antibody response to
infection
Given the apparent Th2 cytokine polarization induced by LCP
vaccination, we hypothesized that the antibody response induced
by the LCP constructs may be distinct from that induced by
plasmid DNA. Blood-stage parasite-specific antibody responses
were undetectable following vaccination with PyCSP DNA
(PyCSP is not expressed in the blood-stage of the parasite life
cycle) but developed rapidly concomitant with patent parasitemia
induced by either sporozoite or blood-stage parasite challenge.
The kinetics of the parasite-specific IgG response of the different
vaccine groups followed a similar pattern (Fig. 6A - only LCP2,
LCP3, and DNA Vaccine shown for simplicity). No significant
differences in the AUC of the IgG response were observed
between the different vaccine groups and further assessmentof the
relative amount of parasite-specific IgM, IgG1 and IgG2a also
failed to show any significant differences (data not shown).
Strikingly, a marked increase in parasite-specific IgE levels was
observed following the resolution of parasitemia in the LCP1
vaccine groups in mice infected with either sporozoites or with
infected RBC (Fig. 7). The generation of an IgE response is a
natural conclusion to a Th2 characterised response [73,74];
curiously, however, this IgE response was not pronounced in mice
immunized with the other LCP vaccines which were not markedly
different from either CpG/alum or plasmid DNA immunized
mice.
LCP vaccines protect against experimental malarial
challenge
Since the most appropriate assessment of a vaccine platform is
capacity to protect against pathogen challenge, naı¨ve mice were
vaccinated with each of the four LCP vaccines or controls
including p-CPG/alum or DNA encoding P. yoelii CSP in a prime-
Figure 6. Parasite-specific IgG response following vaccination
and infection. Mice were vaccinated s.c. three times at 3 week
intervals with lipid core peptides (LCP), or pooled peptides (P1, P2, P3,
P4; see Table 1) and CpG-Alum, or i.m. injection with a DNA vaccine
encoding PyCSP. Seven days after the final vaccination the mice were
challenged by i.v. injection with live P. yoelii sporozoites (SPZ inf) or
parasitized red blood cells (Blood inf). The parasite-specific IgG antibody
response was measured during the course of infection by flow
cytometry (see Materials and Methods) and the area under the curve
(AUC) for each individual mouse calculated. (A) Representative plots
demonstrating the kinetics of the IgG response and the AUC. (B)
Statistical comparisons for all groups. Results from a representative
experiment are shown (n = 7 mice, mean and SEM). Statistical
comparisons were made to a control group that received no
vaccination (No Vacc Ctrl) using one-way ANOVA with Bonferroni’s
post-test (no significant differences noted).
doi:10.1371/journal.pone.0040928.g006
Figure 7. Parasite-specific IgE response following vaccination
and infection. Mice were vaccinated s.c. three times at 3 week
intervals with lipid core peptides (LCP), or pooled peptides (P1, P2, P3,
P4; see Table 1) and CpG-Alum, or i.m. injection with DNA vaccine
encoding PyCSP. Seven days after the final vaccination mice were
challenged by i.v. injection with live P. yoelii sporozoites (SPZ inf) or
parasitized red blood cells (Blood inf). The parasite-specific IgE response
was measured at the timepoints indicated during the course of
infection by flow cytometry (see Materials and Methods). Results from a
representative experiment are shown; statistical comparisons are made
between the LCP1 group and a similarly infected control group that was
not vaccinated using one-way ANOVA with Bonferroni’s post-test (n = 7
mice, mean and SEM).
doi:10.1371/journal.pone.0040928.g007
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boost strategy as described above. Eleven days following the final
vaccination, mice were challenged with 1000 P. yoelii sporozoites.
Liver-stage parasite burden was determined 42 h post-challenge
by RT-PCR of P. yoelii 18S ribosomal RNA (Fig. 8A). In parallel
experiments, mice were allowed to progress to blood-stage
parasitemia (Fig. 8B). The kinetics and burden of blood-stage
infection were monitored to day 35 post-infection (Fig. 8B) and the
ability of the vaccines to inhibit the development of blood-stage
parasitemia was assessed by comparative area under the curve
(AUC) analysis (Fig. 8C).
No mice were sterilely protected following immunization and
sporozoite infection; however, consistent with previous studies
[61], the PyCSP plasmid DNA vaccine conferred significant
protection at the liver-stage as indicated by both significant
reduction in liver-stage parasite burden (Fig. 8A) and blood-stage
parasitemia following sporozoite challenge (Fig. 8B and 8C). LCP3
also conferred a significant reduction in liver-stage parasite burden
and blood-stage parasitemia; whereas LCP1 and LCP2 conferred
protection against liver-stage parasite burden only. Mice immu-
nized with LCP4 or with the pool of CD8+ and CD4+ T cell
epitopes formulated in CpG/alum were not protected at any stage.
Discussion
In 1984, it was reported that conjugation of a dipalmityl-lysine
moiety to a synthetic peptide derived from the hepatitis B surface
antigen (HBsAg) significantly improved the anti-HepB antibody
response, in comparison to the corresponding peptide-keyhole
limpet hemocyanin conjugate [75]. Subsequently it was demon-
strated that influenza virus-specific CD8+ CTL could be primed in
vivo by a synthetic lipopeptide vaccine comprising synthetic peptide
epitopes covalently linked to tripalmitoyl-S-glycerylcysteinyl-seryl-
serine, in the absence of adjuvant, whereas the corresponding
peptide without a lipidic moiety did not [76–78]. It is now well
established that lipopeptides, in particular tripalmitoyl-S-glyceryl
cysteine (Pam3Cys) lipopeptides, constitute potent immunoadju-
vants in animal models, markedly enhancing the epitope-specific
immune response when conjugated to B cell, helper T cell, or
cytotoxic T lymphocyte epitopes; improving vaccine efficiency and
conferring protection against pathogen challenge in animal models
(reviewed in [5,23,79], including malaria [25–28]. Of particular
importance for vaccine development is the ability of lipopeptides
to induce CD8+ T cell and CTL responses (reviewed in [79]),
which are key mediators of protection against intracellular
pathogens. Lipopeptides are thought to induce dendritic cell
(DC) maturation and production of pro-inflammatory cytokines
(with a Th1-bias for palmitoyl-lipopeptides), activating antigen-
specific CD4+ and CD8+ T cell responses via the Toll-like
receptor-2 pathway [80].
Figure 8. Parasite burden and parasitemia following vaccina-
tion and infection. Mice were vaccinated s.c. three times at three
week intervals with lipid core peptides (LCP), or pooled peptides (P1,
P2, P3, P4; see Table 1) and CpG-Alum, or i.m. injection with DNA
vaccine encoding PyCSP. Seven days after the final vaccination mice
were challenged by i.v. injection with live P. yoelii sporozoites (SPZ inf)
or parasitized red blood cells (Blood inf). (A) Liver parasite burden in
sporozoite infected mice, assessed 42 h post infection by RT-PCR of
parasite 18S rRNA (see Materials and Methods) (n = 5 mice, mean and
SEM). (B) Kinetics of parasitemia and (C) area under curve of parasitemia
(AUC); results of pooled data from three repeat experiment are shown
(n= 21 mice, mean and SEM). Statistical comparisons are made to a
control group that received no vaccination (No Vacc Ctrl) using one-way
ANOVA with Bonferroni’s post-test.
doi:10.1371/journal.pone.0040928.g008
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Previously, we have reported a promising vaccine delivery
system, lipid core peptide (LCP) [29,81]. LCP is designed to
incorporate antigen, carrier, and adjuvant in a single molecular
entity. The mode of action of LCP-based vaccine candidates has
been analysed and it was found that, similar to other lipopeptides,
the self-adjuvanting activity of constructs was based on TLR2
mediated DC activation [82–84]. Studies have shown that
incorporation of a monomeric peptide epitope into a LCP
structure could enhanced antibody immunogenicity up to 3200-
fold in a mouse model of Chlamydia [34] and that the magnitude
and specificity of the LCP-induced antibody responses could be
influenced by the number of epitope sequences attached to the
oligomeric polylysine core, the number of lipoamino acids in the
constructs, the length of the alkyl side-chains, or the spacing
between the lipoamino acid units [33,35]. LCP constructs
incorporating defined B cell epitopes have induced highly opsonic
antibodies and conferred protection against infection with Group
A streptococcus in mice even in the absence of adjuvant [31,36].
However, there are no reports of robust LCP-induced T cell
responses. One study showed that an LCP construct consisting of
four copies of a minimal CD8+ T cell epitope attached to a core
containing lipoamino acids stimulated a cytotoxic CD8+ T-cell
response in vivo but only in the presence of alum as an additional
adjuvant [85].
As yet, there is no solid evidence that LCP constructs can access
either MHC class I or class II presentation pathways to induce
epitope-specific T cell responses and confer protection in a T cell
dependent manner. CD4+ T cells recognize peptide epitopes
derived from exogenous antigens taken up by antigen presenting
cells, in association with MHC class II molecules. In contrast,
antigens recognized by CD8+ T cells are generally processed by
the endogenous pathway and presented to CD8+ T cells in
association with MHC class I molecules [86–89]. For exogenous
antigens to be presented in complex with MHC class I they must
be cross-presented (reviewed in [90]) and the lipid moiety of
lipopeptides appears to facilitate cross-presentation, enabling
robust CD8+ T cell responses. However, since the structure of
LCP constructs is more complex than that of lipopeptides, it is not
obvious that LCPs would be similarly processed. Accordingly, the
aim of this study was to determine whether LCP constructs
incorporating defined CD4+ and/or CD8+ T cell epitopes, with or
without specific CD4+ T cell help, could induce epitope-specific
immune response and protect against pathogen challenge in a
rodent model of malaria.
In the work presented herein, LCP vaccines failed to induce an
expansion of antigen-specific CD8+ T cells following primary or
prime-boost immunization. Furthermore, LCP vaccines induced
type 2 polarized cytokine responses and cytotoxic responses that
were not specifically directed against the antigen epitopes. This
was in contrast to the responses elicited by DNA vaccination
which was characterized by a canonical antigen-specific CD8+ T
cell expansion and the production of IFN-c and TNF. The non-
specific LCP-induced responses were nonetheless able to protect
against parasite challenge, since three of the four LCP vaccines
were able to significantly reduce liver-stage parasite burden. The
protective LCPs contained dominant and subdominant CD8+ T
cell epitopes that were not nested within CD4+ T cell epitopes (a
9 mer and 10 mer), whereas the LCP containing dominant CD4+
T cell epitopes spanning those CD8+ T cell epitopes was not
protective (a 16 mer and 14 mer). These findings may reflect an
inability of the LCPs to find their way into the cross-presentation
pathway or an inability of the antigen-presenting cell to cleave the
longer peptides as the 9 mer and 10 mer could conceivably bind
free MHC-I molecules without requiring these functions. This
again contrasts with the DNA immunization which induced
antigen-specific CD8+ T cell expansion, presumably via a
mechanism where antigen-presenting cells cross-present protein
expressed within muscle; although, plasmid DNA taken up
directly, and expressed by antigen-presenting cells, could achieve
the same outcome. Indeed, it remains unknown which cells are
responsible for taking up and presenting the LCPs in our study and
if they are capable of cross-presentation. Further studies will be
required to understand the mechanism of antigen presentation and
type 2 cytokine induction observed in our model and whether
further modification of the LCP-core could promote antigen-
specific CD8+ T cell responses.
Supporting Information
Figure S1 Hemolytic potential of lipid core peptides.
Hemolytic potential of lipid core peptides (LCP) was measured by
comparing the absorbance (540 nm) of blood samples incubated
with the LCP vaccine candidates with that of samples incubated
with a positive control (SDS, 100% hemolysis) and a negative
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